Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT05845671 |
| Title | Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase Ib/II |
| Variant Requirements | Yes |
| Sponsors | University of Colorado, Denver |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Colorado Research Center | RECRUITING | Aurora | Colorado | 80045 | United States | Details |
| Outpatient CTRC | RECRUITING | Aurora | Colorado | 80045 | United States | Details |
| UCHealth Metro Denver | RECRUITING | Aurora | Colorado | 80045 | United States | Details |
| University of Michigan Rogel Cancer Center | RECRUITING | Ann Arbor | Michigan | 48109 | United States | Details |